Mental Disorder Treatment Market Size Trends Analysis and Forecast till 2035
The global Mental Disorder Treatment market was valued at USD 49.4 billion in 2021 and it is expected to hit around USD 80.7 billion by 2030 with a CAGR of 7.6% during the forecast period 2022 to 2030.
A mental disorder is also called as mental illness or a psychiatric disorder. Mental disorders are generally defined according to how an individual behave, feels, perceives and thinks, and mental disorder occurs due to damage or problems associated with functions of brain. There are various types of mental disorders such as depression, bipolar disorder, schizophrenia and other psychoses, dementia, and developmental disorders including autism. These disorders can be treated with the help of various medications such as anti-depressants, antianxiety drugs and can also be treated with self-help therapies such as psychotherapy, brain stimulation treatments, and others.
The increasing prevalence of mental disorders such as depression is expected to propel growth of the global mental disorder treatment market during the forecast period. For instance, according to the World Health Organization report published in 2022, stated that depression is the most common mental disorder globally and around 364 million individuals suffered from depression globally, in the year 2022.
Report on Scope of the Mental Disorder Treatment Market
Segmental Insights
By Disorder Type
How did the depression segment dominate the Mental Disorder Treatment market?
The depression segment is driven by the massive post-pandemic surge in clinical diagnoses and a strategic expansion of disease definitions to include burnout and chronic stress. The high prescription volumes of established SSRIs and the rapid commercialization of next-generation, fast-acting therapies like ketamine and NMDA receptor antagonists. Furthermore, the concentrated market share of pharmaceutical giants in North America and Europe ensures a robust infrastructure for the long-term, continuous treatment of major depressive disorder.
How did the anxiety disorders segment expect to hold the fastest-growing Mental Disorder Treatment market in the coming years?
The anxiety disorders segment is driven by the emergence of digital therapeutics and breakthrough psychedelic-assisted therapies, alongside a shift toward more accessible over-the-counter (OTC) treatment pathways. With its sophisticated healthcare infrastructure and high insurance coverage, developing economies are emerging as the fastest-growing regions due to reduced social stigma. The synergy between technological innovation and increased clinical reporting is defining the next era of global mental healthcare delivery.
By Medication
How did the antidepressants segment account for the largest share in the Mental Disorder Treatment market?
The antidepressants segment is driven by high prevalence and demand surge in conditions, such as major depressive disorder, anxiety, and PTSD, which have increased prescriptions for antidepressants. Increased awareness campaigns and reduced stigma have led to higher diagnosis rates and a patient demand for pharmaceutical interventions. The product innovation and approvals, ongoing development, such as new, rapidly acting antidepressants, keep the market growing.
How did the atypical antipsychotics segment expect to hold the fastest-growing Mental Disorder Treatment market in the coming years?
The atypical antipsychotics segment is driven by offering superior receptor-binding profiles that significantly reduce traditional extrapyramidal side effects. The development of long-acting injectables (LAIs) has dramatically improved patient adherence compared to daily oral medications. This innovation, paired with a rising global patient pool for schizophrenia and treatment-resistant depression, is creating high demand across both developed and emerging markets. The synergy of improved safety profiles and increased clinical awareness is establishing second-generation antipsychotics as a cornerstone of modern psychiatric care.
By Distribution Channel
How did the retail pharmacies segment account for the largest share in the Mental Disorder Treatment market?
The retail pharmacies segment is driven by serving as the primary, most accessible point of contact for patients managing chronic conditions like depression and anxiety. The high level of patient trust in local pharmacists, who provide essential face-to-face counseling and personalized care that digital channels cannot yet fully replicate. The combination of high prescription volumes and a localized infrastructure makes retail pharmacies the foundational pillar of the global mental health distribution network.
How did the online pharmacies segment expect to hold the fastest-growing Mental Disorder Treatment market in the coming years?
The online pharmacies segment is driven by integrating directly with telemedicine platforms; these digital providers create a seamless total healthcare model that combines virtual counseling with automated, door-to-door medication delivery. The adoption of subscription-based auto-refills further ensures long-term treatment adherence, particularly in emerging markets where smartphone penetration is rapidly expanding into Tier 2 and Tier 3 cities.
Key Players in the Mental Disorder Treatment Market
- Allergan plc (now part of AbbVie)
Allergan contributes to the mental disorder treatment market by developing and commercializing branded pharmaceuticals for conditions such as major depressive disorder and bipolar disorder, with notable contributions including Vraylar (cariprazine).
Eli Lilly has a long-standing legacy in neuroscience, contributing to the treatment of serious mental illnesses such as schizophrenia and bipolar disorder through its pharmaceutical portfolio, including Zyprexa (olanzapine).
VistaGen is a clinical-stage biopharmaceutical company pioneering a new class of rapid-onset, nose-to-brain pherine nasal sprays designed to treat anxiety and depression without systemic exposure.
Sanofi contributes to the mental disorder treatment market by leveraging its global pharmaceutical footprint to develop treatments that address psychiatric comorbidities and CNS-related conditions.
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the global Mental Disorder Treatment market
By Disorder Type
- Depression
- Bipolar Disorder
- Schizophrenia
- Dementia
- Post-traumatic Stress Disorder
- Others
By Medication
- Anti-depressants
- Anti-anxiety
- Mood Stabilizing Medication
- Antipsychotic Medications
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Download Sample
Request Customization
Request Customization
Download Sample
